GlaxoSmithKline's (GSK) Pharmaceuticals segment declined substantially in 2015 due to the divestment of its Oncology business to Novartis (NVS) in March 2015. At constant exchange rates, the Pharmaceutical segment reported 3% growth in 2016 revenues at 16.1 billion pounds compared to ~14.2 billion pounds for 2015. The growth was driven by increased sales of HIV products Triumeq and Tivicay, as well as its new pharmaceutical products, which were partially offset by lower sales of Seretide and Advair.